Next Article in Journal
Matrix metalloproteinase-3 gene polymorphism and dilatative pathology of ascending thoracic aorta
Previous Article in Journal
The evaluation of psychomotor development in preterm infants
Medicina is published by MDPI from Volume 54 Issue 1 (2018). Articles in this Issue were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence. Articles are hosted by MDPI on as a courtesy and upon agreement with Lithuanian Medical Association, Lithuanian University of Health Sciences, and Vilnius University.
Open AccessArticle

Comparison in vitro felodipine release rate from the original versus generic product with controlled release of the drug

Department of Pharmaceutics
Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, Brno University of Veterinary and Pharmaceutical Sciences, Czech Republic
Author to whom correspondence should be addressed.
Medicina 2007, 43(4), 326;
Received: 11 April 2006 / Accepted: 30 March 2007 / Published: 4 April 2007
After patent protection of original brand is over, there are a lot of generic products occurring on the pharmaceutical market. It may be the way to reduce the price, but on the other hand, one should expect the same quality and almost identity with original brand, because the development of generic drugs is based on pharmacological properties of the original brand. The aim of this study was to compare the similarity of two products with controlled release of felodipine – generic product Presid® and original brand Plendil® – which are commercially available in Czech Republic, based on in vitro dissolution testing. The dissolution test in three dissolution media of increasing pH (1.2, 4.5, and 6.5) for the simulation of physiological pH within the gastrointestinal tract confirmed controlled release of felodipine from the original product Plendil ER 5 mg and Plendil ER 10 mg during the period of 24 hours. The release of felodipine from generic products Presid 5 mg and Presid 10 mg was not controlled for 24 hours as it is indicated in the information leaflet. In the generic products, felodipine release was controlled just for 12 or 18 hours and in this respect did not show similarity with the original brand. Since patients take the drug just once a day in the morning, the controlled release of felodipine, which lasts only 12 to 18 hours, can cause insufficient blood pressure control especially in the most critical morning hours and higher cardiovascular risk.
Keywords: felodipine; dissolution study; controlled release; comparison felodipine; dissolution study; controlled release; comparison
MDPI and ACS Style

Vetchy, D.; Vetcha, M.; Rabiškova, M.; Gryczova, E.; Bartošikova, L. Comparison in vitro felodipine release rate from the original versus generic product with controlled release of the drug. Medicina 2007, 43, 326.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop